Condition: Ovarian Cancer · Ovarian Carcinoma · Recurrent Ovary Cancer · Sponsor: Elizabeth Stover, MD, PhD
The purpose of this research study is determining the highest dose of the study drug DT2216 in combination with paclitaxel that can be safely and tolerably administered in recurrent ovarian cancer. The names of the study drugs involved in this study are: * DT2216 (a type of proteolysis-targeting chimera degrader of BCL-XL protein) * Paclitaxel (a type of antimicrotubule agent)
This description comes directly from the study's public registry record.
Elizabeth Stover, MD, PhD · 617-632-6866 · elizabeth_stover@dfci.harvard.edu
Always discuss trial participation with your own doctor first.
| Beth Israel Deaconess Medical Center (BIDMC) | Boston, Massachusetts, United States | Recruiting |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Brigham and Women's Hospital | Boston, Massachusetts, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06964009